Heart failure & cardiomyopathiesSecondary analysis
Efficacy and Safety of Omecamtiv Mecarbil in Heart Failure With Reduced Ejection Fraction According to Age
- Secondary analysis of the GALACTIC-HF randomised trial
- double-blind
- global
- prespecified age subgroups
Authors' conclusion
Treatment with omecamtiv mecarbil was safe irrespective of age and reduced the risk of CV death or first HF event across the age spectrum, especially in those with severe HF.
Study context
- Population
- Symptomatic HFrEF (age 18–85 years, elevated natriuretic peptides, left ventricular ejection fraction (LVEF) ≤35%)54.5% ≥65 years
- Participants
- 8,232 participants
- Comparison
- Omecamtiv mecarbil vs placebo, by age
- Primary endpoint
- CV death or first HF event (hospitalization or urgent visit for HF)
Primary result
CV death or first HF event, by age
Hazard ratio
0.92
95% CI 0.86–0.99
P = 0.03
Omecamtiv mecarbil vs Placebo
HR 0.92 (95% CI 0.86–0.99); P = 0.03
As reported in the abstract
per 100 py
- Primary outcome rate, <65 years
- 21.4
- Primary outcome rate, ≥65 years
- 28.8
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| CV death or first HF event, severe HF subgroup by age — Omecamtiv mecarbil vs Placebo · <65 years | 0.77 (0.64–0.92) | |
| CV death or first HF event, severe HF subgroup by age — Omecamtiv mecarbil vs Placebo · ≥65 years | 0.83 (0.71–0.97) | |
| 0.512Hazard ratio (log scale) |
- Cardiovascular (CV) death or first heart failure (HF) event, severe HF subgroup by age: interaction P = 0.47
Safety
Safety profile by age
- Safety profile consistent irrespective of age
- P for interaction > 0.05 for all
Original publication
Efficacy and Safety of Omecamtiv Mecarbil in Heart Failure With Reduced Ejection Fraction According to Age. JACC Heart Fail. Published 22 October 2025. doi:10.1016/j.jchf.2025.102703
Summarised from the published abstract; every number is checked against it